Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Paracetamol and Amantadine Dispersible Tablets is a combination small molecule drug developed by Shandong Zibo Xinda Pharmaceutical for the symptomatic relief of cold and flu. The formulation combines paracetamol (acetaminophen), which acts on central COX/analgesic pathways to provide antipyretic and analgesic effects, with amantadine, which targets the influenza A M2 protein to inhibit viral replication and also has dopaminergic and NMDA receptor effects. The drug is administered orally as a dispersible tablet and is approved for use in relieving symptoms such as fever, headache, body aches, and other manifestations of common cold and influenza. This combination product leverages the complementary mechanisms of its active ingredients to address both the viral cause (in the case of influenza A) and the symptomatic manifestations of respiratory infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Paracetamol and Amantadine Dispersible Tablets.